Multimodal image-guided resection of IDH-wildtype glioblastoma and grade IV IDH-mutant astrocytoma

Conditions: brain tumor
glioblastoma
10029211
10009720

Registration Number: NL-OMON56595

Lead Sponsor: Amsterdam UMC

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

- Age >= 18 years
- New clinical and radiological suspected diagnosis of IDH-wildtype
glioblastoma or grade IV IDH-mutant astrocytoma
- Indication for a surgical resection and adjuvant treatment according to the
neuro oncology multidisciplinary meeting
- Eligible for a supramarginal resection according to two neurosurgeons in
consensus
- Karnofsky Performance Score (KPS) >= 70

Exclusion Criteria

- Previous brain surgery or cranial radiotherapy
- Significant other brain pathology, in the opinion of the PI or designee, such
as multiple sclerosis, neurodegenerative disease, stroke
- Tumor located infratentorially or in the spinal cord
- Lack of adequate social or family support needed for adherence to the further
postoperative therapeutic regimen
- Pregnancy

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoint is the optimization of ADC/FET-guided resection.<br /><br>Volumetric and percentual extent of resection, as measured with MRI and PET<br /><br>imaging, combined with surgery-induced morbidity will be used as outcome<br /><br>parameters. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary study parameters will be the histopathology-based diagnostic<br /><br>accuracy of APT-CEST MRI in comparison with FET PET, cognitive performance over<br /><br>time and progression free survival.</p><br>